Company Update (NASDAQ:ARWR): Arrowhead Pharmaceuticals Inc Presents Promising ARC-520 Hepatitis B Data at The International Liver Congress™ 2016

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced that three presentations are being made on ARC-520, its investigational medicine for the treatment of chronic hepatitis B infection, at The International Liver Congress™ 2016 (ILC 2016), in Barcelona, Spain, April 13-17, 2016.

Collectively, these presentations demonstrate several important findings from Arrowhead’s clinical and nonclinical studies of ARC-520, including the following:

  • ARC-520 and entecavir produced rapid HBV DNA suppression with all hepatitis B e-antigen (HBeAg) positive, treatment naïve patients achieving serum HBV DNA reductions of up to 5.5 log (99.9997%), and all HBeAg negative, treatment naïve patients achieving reductions that put them below the limit of quantitation
  • ARC-520 effectively inhibited HBV cccDNA-derived mRNA with observed viral protein reduction in HBV patients of up to 2.0 log (99%) after a single dose
  • Based on HBsAg epitope profile analysis, poster authors and Arrowhead collaborators had previously identified a predictive hepatitis B surface-antigen (HBsAg) Clearance Profile associated with HBsAg clearance in antiviral therapy cohorts
  • There was a significant association between the development of an HBsAg Clearance Profile and ARC-520 therapy in HBV patients
  • Complexed HBsAg antibodies (anti-HBs) were developed and detected in HBV patients treated with ARC-520, which may represent a recovery of the immune system response
  • After monthly administration of 6-11 doses of ARC-520 in chimpanzees chronically infected with HBV, the ARC-520 target site sequences remained virtually unchanged, indicating that no drug resistance developed during the treatment period

Chris Anzalone, Ph.D., president and CEO of Arrowhead Pharmaceuticals, said: “These are exciting results that continue to show that ARC-520 can reduce the production of HBV viral proteins. We have ongoing multiple-dose and combination studies designed to assess if this will allow the body’s natural immune defenses to control the virus and lead to a functional cure.” (Original Source)

Shares of Arrowhead are up nearly 3% to $5.40 in pre-market trading. ARWR has a 1-year high of $9.36 and a 1-year low of $3.07. The stock’s 50-day moving average is $4.55 and its 200-day moving average is $4.99.

On the ratings front, Arrowhead has been the subject of a number of recent research reports. In a report issued on March 31, Jefferies Co. analyst Eun Yang reiterated a Hold rating on ARWR, with a price target of $4, which implies a downside of 24.0% from current levels. Separately, on February 10, Piper Jaffray’s Edward Tenthoff maintained a Buy rating on the stock and has a price target of $13.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Eun Yang and Edward Tenthoff have a total average return of -4.3% and -5.6% respectively. Yang has a success rate of 53.7% and is ranked #3393 out of 3790 analysts, while Tenthoff has a success rate of 33.6% and is ranked #3520.

Arrowhead Pharmaceuticals, Inc. engages as a biopharmaceutical company developing targeted RNAi therapeutics. Its pipeline includes clinical programs in chronic hepatitis B virus and partner based programs in obesity and oncology. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.


Stay Ahead of Everyone Else

Get The Latest Stock News Alerts